Vasella wins chairman role at Alcon

Novartis Chairman Daniel Vasella (photo) was elected to the additional position of board chairman of Alcon, a move that further asserts Novartis's control of the eye-care company as it seeks to buy the 23 percent it doesn't already own. Report

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.